OXiGENE to Present at Roth Capital Partners 17th Annual OC Conference:

    Business Editors/Health Editors
    Roth Capital Partners 17th Annual Growth Stock Conference
    BIOWIRE2K

    WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 18, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), today announced that President and Chief Executive Officer Fred Driscoll will present at Roth Capital Partners 17th Annual OC Conference, at the St. Regis Monarch Beach Resort and Spa in Dana Point, California..
    The Roth presentation is scheduled to begin at 3:30 PT Tuesday, February 22, 2005. A live and archived webcast will be available on OXiGENE's website, www.oxigene.com. From the home page, click on the "Calendar of Events" link under the tab labeled "Press Room". Please log on five minutes prior to the event to ensure the proper software is downloaded and installed.
    Roth Capital Partners' OC Conference takes place February 21-23. The conference is scheduled to feature more than 220 companies in the Technology, Healthcare, Financial Services and Consumer Products sectors. This concentrated program will allow institutional investors to meet the executives from a select group of companies that have been picked by Roth's research team.

    About OXiGENE, Inc.

    OXiGENE is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

--30--MP/bo*

CONTACT: MacDougall BioCommunications Chris Erdman, 508-647-0209 chris@macbiocom.com

KEYWORD: MASSACHUSETTS TRACK INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY TRADESHOW SOURCE: OXiGENE, Inc.

Copyright Business Wire 2005